InvestSMART

AdAlta Limited (ASX:1AD)

ALERT: Price-sensitive ASX Announcement for 1AD
Current share price for 1AD : $0.003 -0.001 (-25%)+
Announcement
Release
29 Jul 2026 9:23AM
Price at Release
$0.004
Full Release
download
Summary
AdAlta Limited, an Australian biotechnology company, provided its quarterly Appendix 4C and activities report for the period ending 30 June 2026. The company continued advancing its 'East to West' strategy, focusing on capital-efficient development of CAR-T cell therapies. Key developments included the completion of an initial investment in EW-001, a CAR-T therapy for mesothelioma, securing manufacturing rights and progressing regulatory engagements with the US FDA. AdAlta raised additional funds through equity to support these initiatives and enhanced its capabilities by leveraging artificial intelligence. The report reflects AdAlta's strategic positioning in the cellular immunotherapy market, with a focus on solid cancers.
Key Points
  • Completed initial investment in EW-001 CAR-T therapy.
  • Advanced Australian manufacturing and US FDA engagement.
  • Secured $1.39 million milestone payment for development outside Greater China.
  • Increased AI capabilities through collaboration with Oktopi.
  • Raised $2.5 million from equity to fund operations.
  • Focused on 'East to West' strategy for capital-efficient development.
  • Recognized for model and strategy in cellular immunotherapy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.